R&G PharmaStudies Co., Ltd. (SHE:301333)
China
· Delayed Price · Currency is CNY 63.47
-2.36 (-3.58%)
At close: Apr 29, 2026
R&G PharmaStudies Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | 133.65 | 136.9 | 140.22 | 162.53 | 113.45 | 99.24 | Upgrade
|
| Depreciation & Amortization | 20.33 | 20.33 | 36.31 | 34.57 | 19.03 | 36.05 | Upgrade
|
| Other Amortization | 17.06 | 17.06 | 1.4 | 2.19 | 17.4 | 1.59 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.01 | 0.01 | 0.07 | 0.02 | 0.02 | 0.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 0 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -21.1 | -21.1 | -24.95 | -27.44 | -9.14 | -2.6 | Upgrade
|
| Provision & Write-off of Bad Debts | 5.19 | 5.19 | 3.36 | 4.86 | 3.57 | 7.54 | Upgrade
|
| Other Operating Activities | 4.65 | 8.28 | 4.96 | 0.23 | -3.56 | 3.29 | Upgrade
|
| Change in Accounts Receivable | -49.72 | -49.72 | -54.95 | -20.08 | -42.52 | -58.34 | Upgrade
|
| Change in Inventory | 6.22 | 6.22 | -4.23 | 1.75 | -9.74 | -14.6 | Upgrade
|
| Change in Accounts Payable | 6.88 | 6.88 | 52.19 | 21.66 | 42.55 | 43.5 | Upgrade
|
| Change in Other Net Operating Assets | -13.98 | -13.98 | -0.02 | 13.27 | 0.22 | 0.36 | Upgrade
|
| Operating Cash Flow | 107.32 | 114.2 | 154.76 | 192.56 | 130.47 | 114.57 | Upgrade
|
| Operating Cash Flow Growth | -10.77% | -26.21% | -19.63% | 47.60% | 13.87% | 159.80% | Upgrade
|
| Capital Expenditures | -18.79 | -19.28 | -19.98 | -19.88 | -20.83 | -38.28 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.01 | 0.01 | 0.01 | 0.02 | 0.15 | 0.09 | Upgrade
|
| Cash Acquisitions | -24 | -24 | -21.31 | - | - | - | Upgrade
|
| Investment in Securities | 330.67 | 41.5 | -26 | -710 | - | - | Upgrade
|
| Other Investing Activities | 17.36 | 20.87 | 22.95 | 25.05 | 9.14 | 2.6 | Upgrade
|
| Investing Cash Flow | 305.24 | 19.11 | -44.33 | -704.8 | -11.54 | -35.59 | Upgrade
|
| Short-Term Debt Issued | - | - | 54.79 | - | - | - | Upgrade
|
| Total Debt Issued | - | - | 54.79 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -69.01 | -14.36 | -12.74 | -11.5 | -9.94 | Upgrade
|
| Net Debt Issued (Repaid) | -13.87 | -69.01 | 40.43 | -12.74 | -11.5 | -9.94 | Upgrade
|
| Issuance of Common Stock | 1.01 | 1.01 | 15.18 | - | 1,114 | - | Upgrade
|
| Repurchase of Common Stock | - | - | -56.09 | - | - | - | Upgrade
|
| Common Dividends Paid | -16.78 | -11.78 | -28.38 | -5.82 | - | - | Upgrade
|
| Other Financing Activities | -2.48 | 10.75 | -19.87 | - | -66.99 | - | Upgrade
|
| Financing Cash Flow | -32.12 | -69.03 | -48.74 | -18.56 | 1,036 | -9.94 | Upgrade
|
| Foreign Exchange Rate Adjustments | -6.38 | -3.72 | 1.76 | 1.1 | 5.44 | -1.27 | Upgrade
|
| Net Cash Flow | 374.06 | 60.56 | 63.44 | -529.69 | 1,160 | 67.77 | Upgrade
|
| Free Cash Flow | 88.52 | 94.93 | 134.78 | 172.68 | 109.64 | 76.29 | Upgrade
|
| Free Cash Flow Growth | -11.07% | -29.57% | -21.95% | 57.50% | 43.71% | 309.66% | Upgrade
|
| Free Cash Flow Margin | 9.88% | 11.15% | 18.12% | 23.94% | 17.20% | 12.54% | Upgrade
|
| Free Cash Flow Per Share | 0.93 | 0.99 | 1.41 | 1.80 | 1.33 | 1.06 | Upgrade
|
| Cash Income Tax Paid | 56.91 | 58.34 | 52.15 | 55.1 | 40.9 | 45.16 | Upgrade
|
| Levered Free Cash Flow | 18.67 | 64.94 | 116.07 | 133.19 | 80.6 | 44.54 | Upgrade
|
| Unlevered Free Cash Flow | 20.46 | 66.73 | 118.22 | 133.56 | 81.02 | 44.9 | Upgrade
|
| Change in Working Capital | -52.47 | -52.47 | -6.62 | 15.6 | -10.3 | -30.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.